A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies

Matthew H. Taylor, Ajjai S. Alva, Timothy Larson, Sebastian Szpakowski, Das Purkaystha, Alpesh Amin, Linda Karpiak, Sarina A. Piha-Paul

    Research output: Contribution to journalArticle

    Abstract

    Background: Receptor tyrosine kinases (RTKs) play key roles in tumorigenesis. The multi-RTK inhibitor dovitinib has demonstrated promising antitumor activity in multiple cancers. Patients and Methods: In this phase 2, open-label, single-arm study, patients with advanced malignancies with RTK-pathway genetic aberrations whose disease progressed on/following standard treatment received dovitinib (500 mg/day; 5-days-on/2-days-off). The primary endpoint was clinical benefit rate (CBR; complete response, partial response [PR], or stable disease [SD] for ≥ 16 weeks). Results: Of 80 patients enrolled, common tumors included gastrointestinal stromal tumors (GIST; 20.0%), colorectal cancer (CRC; 18.8%), and ovarian cancer (10.0%). Patients were heavily pretreated (median prior lines = 4; 67.5% had ≥ 3 prior lines). Genetic aberrations included cKIT (28.8%), FGFR3 (15.0%), and RET (15.0%). The CBR was 13.8%; one PR (GIST) and 10 SD (adenoid cystic [n = 3]; ovarian [n = 3]; GIST [n = 2]; CRC [n = 1]; gastroesophageal junction [n = 1]). The most common treatment-related adverse events were fatigue, diarrhea, nausea, and vomiting. Conclusions: In this heterogeneous patient population, the safety profile was acceptable for dovitinib therapy. A subset of patients with RTK pathway-activated tumors experienced clinical benefit. However, the primary endpoint was not met, suggesting further refinement of predictive biomarkers is required.

    Original languageEnglish (US)
    Pages (from-to)1235-1243
    Number of pages9
    JournalOncotarget
    Volume11
    Issue number14
    DOIs
    StatePublished - Apr 1 2020

    Keywords

    • Advanced malignancies
    • Basket trial
    • Dovitinib
    • Histology-agnostic
    • Mutation-specific

    ASJC Scopus subject areas

    • Oncology

    Fingerprint Dive into the research topics of 'A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies'. Together they form a unique fingerprint.

  • Cite this

    Taylor, M. H., Alva, A. S., Larson, T., Szpakowski, S., Purkaystha, D., Amin, A., Karpiak, L., & Piha-Paul, S. A. (2020). A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. Oncotarget, 11(14), 1235-1243. https://doi.org/10.18632/oncotarget.27530